Skip to main content

RX Updates

Vasculitis Update

Sponsored by Novartis Pharmaceuticals Corporation
GCA and PMR: Overview of Diseases Giant cell arteritis (GCA) is the most common vasculitis in the United States, with polymyalgia rheumatica (PMR) being the second most common inflammatory rheumatic disease.1-3 The 2 disorders share an overlap in clinical presentation although they have different diagnoses. Of the patients with a primary diagnosis of GCA, 40% to 60% have PMR, whereas of patients with a primary diagnosis of PMR, 15% to 20% have GCA.1

Long-Term Efficacy and Safety of a JAKi in RA

Sponsored by AbbVie Medical Affairs
Watch rheumatologist Dr. Stan Cohen share his clinical perspective on long-term data with a JAKi in RA. In this video, Dr. Cohen discusses the potential benefits and risks of using a JAKi in TNFi-IR patients.

Mechanism of Action of an Interleukin (IL)–23 Inhibitor Monoclonal Antibody in Moderate to Severe Plaque Psoriasis and Active Psoriatic Arthritis

Sponsored by Janssen Biotech, Inc.
This disease education update from Janssen provides an overview of an interleukin (IL)-23 inhibitor.

Disease Modification in Lupus and Lupus Nephritis: Modifying the Natural Course of the Disease

Sponsored by GSK US Medical Affairs
Discover how you can apply the concept of disease modification in lupus and lupus nephritis to help treat patients in your clinical practice. View our infographic and walk through an interactive patient journey towards disease modification. Also, listen to leading expert Dr. Michelle Petri to learn about scientific advances in monitoring for renal damage accrual in lupus nephritis.

Heart to Heart: Experts Discuss Cardiovascular Risk in Rheumatoid Arthritis

Sponsored by AbbVie Medical Affairs
Tune in as rheumatologists Dr. Christina Charles-Schoeman and Dr. Roy Fleischmann discuss how you can help mitigate cardiovascular risk in your patients with rheumatoid arthritis.

Women in Rheumatology: Gender Issues in Disease and Management

Sponsored by Bristol Myers Squibb
Nine videos discussing gender differences in axSpA, PsA, Vasculitis, Lung Disease, Osteoporosis, Disparities in Healthcare, and Rheumatologic Activity and Treatment, are now available.

Biologics in Lupus - Why, Who and When?

Sponsored by GSK US Medical Affairs
Leading experts from the SLE Educators’ Network discuss how biologic therapies may help address key unmet needs in lupus, while highlighting how clinicians can identify the most appropriate patients for biologic treatment.

A Rheum & Derm Perspective on Treating PsA and Moderate-to-Severe PsO

Sponsored by Lilly USA
Dr. Mease and Dr. Armstrong discuss a multidisciplinary approach and important considerations when treating patients with joint and skin concerns. Ages 18+; for HCPs only.

Solving Still's Disease

Dr. Jack Cush reviews the history, manifestations, diagnosis and treatment of Still's disease.

An Anti-IL-23 in Active Psoriatic Arthritis and Moderate to Severe Plaque Psoriasis

Sponsored by Janssen Biotech, Inc
Plaque psoriasis (PsO) and psoriatic arthritis (PsA) are disorders of the immune system driven primarily by dysregulated T cells. Studies suggest that the Interleukin (IL)-23/Th-17 axis is one of the pathways involved in the pathogenesis of PsO and PsA.

Expert Perspectives on SLE Pathophysiology and the Importance of Changing the Course of Disease

Sponsored by GSK US Medical Affairs
Leading experts from the SLE Educators' Network take us through the pathophysiology of SLE as we understand it today, and discuss the need to change the course of disease as a key treatment goal.

The Future of PsA

As we conclude our PsA campaign, Dr. Ogdie shares information about Preventing PsA and Dr. Ritchlin discusses Future Discovery and Targets.